Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Patricia A. M. Kracht"'
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background The hepatitis C virus (HCV) infection is a candidate disease for micro-elimination. Accurate baseline HCV prevalence estimation is essential to monitor progress to micro-elimination but can be methodologically challenging in low-e
Externí odkaz:
https://doaj.org/article/38829b21a2b646d8ba6e4125b2830865
Autor:
Patricia A. M. Kracht, Elisabeth A. de Gee, Agnes van der Poel, Marc A. M. T. Verhagen, Andy I. M. Hoepelman, Esther A. Croes, Joop E. Arends
Publikováno v:
Harm Reduction Journal, Vol 16, Iss 1, Pp 1-10 (2019)
Abstract Background People who inject drugs (PWID) are disproportionally affected by the hepatitis C virus (HCV) infection. In the Netherlands, active HCV transmission in PWID has practically been halted but uptake of HCV testing and linkage to care
Externí odkaz:
https://doaj.org/article/bed9f0e432a34a57af1f663443b682d9
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0230756 (2020)
PLoS ONE
PLoS ONE
Background In the foreseeable future, patients with hepatitis C virus (HCV) with good healthcare access will all have been cured and the lost to follow-up (LFU) HCV-population will increasingly exist of hard-to-reach patients. Efforts to retrieve the
Autor:
Andy I. M. Hoepelman, M. A. M. T. Verhagen, A.M.J. Wensing, Greet J. Boland, Marjolein P. H. Deege, Patricia A. M. Kracht, P.H.G.M. Stadhouders, Bart J. M. Vlaminckx, Marieke Dimmendaal, Karel J. van Erpecum, Steven F. T. Thijsen, Annemarie J. L. Weersink, Joop E. Arends, Philip W. Friederich
Publikováno v:
Liver International, 39(3), 455. Wiley-Blackwell
Background The Netherlands is one of the six European countries considered on track to eliminate hepatitis C virus by 2030. To achieve this goal, continuous efforts have to be put into designing efficient case-finding strategies, including the retrie
Publikováno v:
Bijblijven. 34:530-540
Virale hepatitis is een leverontsteking die wordt veroorzaakt door ‘hepatotrope virussen’, zoals hepatitis A tot en met E, die hoofdzakelijk levercellen infecteren. Het hepatitis A‑ en E‑virus (HAV en HEV) hebben een feco-orale transmissierou
Autor:
Elisabeth A. de Gee, Agnes van der Poel, Patricia A. M. Kracht, Esther A. Croes, Andy I. M. Hoepelman, Joop E. Arends, M.A.M.T. Verhagen
Publikováno v:
Harm Reduction Journal
Harm Reduction Journal [E], 16(1). BioMed Central
Harm Reduction Journal, Vol 16, Iss 1, Pp 1-10 (2019)
Harm Reduction Journal [E], 16(1). BioMed Central
Harm Reduction Journal, Vol 16, Iss 1, Pp 1-10 (2019)
Background People who inject drugs (PWID) are disproportionally affected by the hepatitis C virus (HCV) infection. In the Netherlands, active HCV transmission in PWID has practically been halted but uptake of HCV testing and linkage to care remains i
Autor:
E. A. Croes, Patricia A. M. Kracht, K.J. van Erpecum, J. A. Willemse, A. I. M. Hoepelman, A. Urbanus, Joop E. Arends
Publikováno v:
Hepatology, Medicine and Policy
Hepatology, Medicine and Policy, Vol 3, Iss 1, Pp 1-10 (2018)
Hepatology, medicine and policy, 3
Hepatology, Medicine and Policy, Vol 3, Iss 1, Pp 1-10 (2018)
Hepatology, medicine and policy, 3
s The Netherlands is striving to achieve national elimination of the hepatitis C virus (HCV) as one of the first countries worldwide. The favorable HCV epidemiology with both low prevalence and incidence, together with access to care and treatment, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80599889539f49536b227da65751fb90
http://hdl.handle.net/10029/622261
http://hdl.handle.net/10029/622261
Autor:
Faydra I. Lieveld, Linde Amelung, Patricia A. M. Kracht, Karel J. van Erpecum, Joop E. Arends, Andy I. M. Hoepelman, Carina J.R. Verstraete, Eveline P. Mauser-Bunschoten, Joep de Bruijne, Peter D. Siersema
Publikováno v:
Infectious Diseases and Therapy
Infectious Diseases and Therapy, 7, 3, pp. 373-385
Infectious Diseases and Therapy, 7(3), 373. Springer Healthcare
Infectious Diseases and Therapy, 7, 373-385
Infectious Diseases and Therapy, 7, 3, pp. 373-385
Infectious Diseases and Therapy, 7(3), 373. Springer Healthcare
Infectious Diseases and Therapy, 7, 373-385
Introduction: Pegylated interferon-based therapy for hepatitis C virus (HCV) negatively impacts nutritional state and patient-reported outcomes (PROs) such as health-related quality of life (HRQL). Clinical trials with direct-acting antivirals (DAAs)
Autor:
Annemarie J. L. Weersink, Joop E. Arends, G. J. Boland, Pieter Friederich, Steven F. T. Thijsen, Marjolein P. H. Deege, M.A.M.T. Verhagen, P.H.G.M. Stadhouders, A. I. M. Hoepelman, K.J. van Erpecum, Bart J. M. Vlaminckx, Patricia A. M. Kracht
Publikováno v:
Journal of Hepatology. 68:S314-S315
Publikováno v:
Clinical Microbiology and Infection, 22(10), 846. Elsevier Limited
In recent years a revolution in hepatitis C virus drug development has taken place from troublesome regimens with pegylated interferon-alfa for 24 to 48 weeks with limited success to all-oral single tablet regimens taken for 12 weeks with very high c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc2addb7443d20144cd46dbb74f7fb7b
https://dspace.library.uu.nl/handle/1874/343061
https://dspace.library.uu.nl/handle/1874/343061